Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):965-9. doi: 10.1016/j.pnpbp.2011.01.015. Epub 2011 Feb 1.
Increasing attention has been paid recently to the potential diabetogenic effect of second-generation antipsychotics (SGAs). The objective of this prospective study was to evaluate the effects of quetiapine treatment on pancreatic beta-cell function in SGA-naïve schizophrenic patients. Seventeen schizophrenic subjects completed an eight-week trial. The metabolic parameters were assessed at weeks 0, 2, 4, and 8. We measured glucose homeostasis with the intravenous glucose tolerance test. After the eight-week treatment, body weight and body mass index showed to be significantly increased compared to those at baseline. No significant changes were found in serum levels of fasting glucose, insulin, total cholesterol, and high-density lipoprotein. Insulin resistance and insulin secretion were significantly increased. Incidences of clinically significant weight gain and treatment-emergent metabolic syndrome were 11.8% and 11.8%, respectively. This study result confirms the association of quetiapine treatment and impairment of glucose homeostasis in schizophrenic patients.
最近，人们越来越关注第二代抗精神病药物（SGAs）的潜在致糖尿病作用。本前瞻性研究的目的是评估喹硫平治疗对 SGA 初治精神分裂症患者胰岛β细胞功能的影响。17 例精神分裂症患者完成了为期 8 周的试验。代谢参数在 0、2、4 和 8 周时进行评估。我们通过静脉葡萄糖耐量试验来评估葡萄糖稳态。经过 8 周的治疗，体重和体重指数与基线相比明显增加。空腹血糖、胰岛素、总胆固醇和高密度脂蛋白的血清水平没有明显变化。胰岛素抵抗和胰岛素分泌明显增加。临床显著体重增加和治疗后代谢综合征的发生率分别为 11.8%和 11.8%。本研究结果证实了喹硫平治疗与精神分裂症患者糖代谢紊乱之间的关联。
